Digest Network Come funziona
Network
/
Società
Ka
Non verificato

KalVista Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

82 comunicati stampa

Guarda tutti i comunicati
04/03/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Scienza
Farmaceutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/03/2026
Eventi
Industria
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Scienza
Farmaceutica
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Salute
Scienza
Farmaceutica
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/02/2026
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Eventi
Industria
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Scienza
Farmaceutica
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Pubblico Esercizio/Vendita al dettaglio
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
22/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Eventi
Industria
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
Fonte
KalVista Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0